A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans (The Journal of Clinical Investigation (2010) 120, 2, (645) DOI: 10.1172/JCI38543);A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans

Journal of Clinical Investigation

Volumn 119, Issue 10, 2009, Pages 3127-3137

  Mandinova, Anna ^a   Kolev, Vihren ^a   Neel, Victor ^a   Hu, Bing ^b   Stonely, Wesley ^a   Lieb, Jocelyn ^a   Wu, Xunwei ^a   Colli, Claudia ^a   Han, Rong ^a   Pazin, Mike ^c   Ostano, Paola ^d   Dummer, Reinhard ^e   Brissette, Janice L ^a   Dotto, G Paolo ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c NATIONAL INSTITUTE ON AGING   (United States)

^d Laboratory of Cancer Pharmacogenomics   (Italy)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 3; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXN1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CONTROLLED STUDY; DEREGULATION; FEEDBACK SYSTEM; FEMALE; GENE EXPRESSION PROFILING; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATINOCYTE; MOUSE; NONHUMAN; ONCOGENE RAS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SEBORRHEIC KERATOSIS; SIGNAL TRANSDUCTION; SKIN TUMOR; SQUAMOUS CELL CARCINOMA;

EID: 70349659643     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI38543C1     Document Type: Erratum

References (61)

1. Owens, D.M., and Watt, F.M. 2003. Contribution of stem cells and differentiated cells to epidermal tumours. Nat. Rev. Cancer. 3:444-451. (Pubitemid 37328848)
2. Alam, M., and Ratner, D. 2001. Cutaneous squamous-cell carcinoma. N. Engl. J. Med. 344:975-983.
3. Albert, M.R., and Weinstock, M.A. 2003. Keratinocyte carcinoma. CA Cancer J. Clin. 53:292-302.
4. Brash, D.E., et al. 1996. Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion. J. Investig. Dermatol. Symp. Proc. 1:136-142.
5. Boyle, J.O., et al. 1993. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res. 53:4477-4480. (Pubitemid 23304366)
6. Di Como, C.J., et al. 2002. p63 expression profiles in human normal and tumor tissues. Clin. Cancer Res. 8:494-501. (Pubitemid 34193969)
7. Brinkman, B.M., and Wong, D.T. 2006. Disease mechanism and biomarkers of oral squamous cell carcinoma. Curr. Opin. Oncol. 18:228-233. (Pubitemid 43740416)
8. Rho, O., Beltran, L.M., Gimenez-Conti, I.B., and DiGiovanni, J. 1994. Altered expression of the epidermal growth factor receptor and transforming growth factor-alpha during multistage skin carcinogenesis in SENCAR mice. Mol. Carcinog. 11:19-28. (Pubitemid 24337381)
9. Lefort, K., et al. 2007. Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKalpha kinases. Genes Dev. 21:562-577. (Pubitemid 46409471)
10. Mandinova, A., et al. 2008. The FoxO3a gene is a key negative target of canonical Notch signalling in the keratinocyte UVB response. EMBO J. 27:1243-1254. (Pubitemid 351574747)
11. Kolev, V., et al. 2008. EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer. Nat. Cell Biol. 10:902-911.
12. Stulberg, D.L., Clark, N., and Tovey, D. 2003. Common hyperpigmentation disorders in adults: Part II. Melanoma, seborrheic keratoses, acanthosis nigricans, melasma, diabetic dermopathy, tinea versicolor, and postinflammatory hyperpigmentation. Am. Fam. Physician. 68:1963-1968. (Pubitemid 37464327)
13. Toussaint, S., Salcedo, E., and Kamino, H. 1999. Benign epidermal proliferations. Adv. Dermatol. 14:307-357.
14. zur Hausen, H. 2000. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J. Natl. Cancer Inst. 92:690-698.
15. Lee, E.S., Whang, M.R., and Kang, W.H. 2001. Absence of human papillomavirus DNA in non-genital seborrheic keratosis. J. Korean Med. Sci. 16:619-622.
16. Pariser, R.J. 1998. Benign neoplasms of the skin. Med. Clin. North Am. 82:1285-1307, v-vi.
17. Nakamura, H., et al. 2001. Clonal nature of seborrheic keratosis demonstrated by using the polymorphism of the human androgen receptor locus as a marker. J. Invest. Dermatol. 116:506-510. (Pubitemid 32299837)
18. Hafner, C., et al. 2007. Spectrum of FGFR3 mutations in multiple intraindividual seborrheic keratoses. J. Invest. Dermatol. 127:1883-1885. (Pubitemid 47075362)
19. Hafner, C., et al. 2006. High frequency of FGFR3 mutations in adenoid seborrheic keratoses. J. Invest. Dermatol. 126:2404-2407. (Pubitemid 44582261)
20. Logie, A., et al. 2005. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum. Mol. Genet. 14:1153-1160. (Pubitemid 40613904)
21. Hafner, C., et al. 2007. Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proc. Natl. Acad. Sci. U. S. A. 104:13450-13454. (Pubitemid 47293965)
22. Mohammadi, M., Olsen, S.K., and Ibrahimi, O.A. 2005. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev. 16:107-137. (Pubitemid 40616111)
23. Burke, D., Wilkes, D., Blundell, T.L., and Malcolm, S. 1998. Fibroblast growth factor receptors: lessons from the genes. Trends Biochem. Sci. 23:59-62. (Pubitemid 28085228)
24. Freier, K., et al. 2007. Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). Oral Oncol. 43:60-66. (Pubitemid 46162249)
25. Grose, R., et al. 2007. The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer development. EMBO J. 26:1268-1278. (Pubitemid 46398706)
26. Hafner, C., et al. 2006. Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J. Clin. Invest. 116:2201-2207. (Pubitemid 44162329)
27. Knowles, M.A. 2007. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J. Urol. 25:581-593.
28. Junker, K., et al. 2008. Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations. Neoplasia. 10:1-7. (Pubitemid 351170708)
29. Black, P.C., and Dinney, C.P. 2008. Growth factors and receptors as prognostic markers in urothelial carcinoma. Curr. Urol. Rep. 9:55-61.
30. Onwuazor, O.N., et al. 2003. Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients. Blood. 102:772-773.
31. Chesi, M., Bergsagel, P.L., and Kuehl, W.M. 2002. The enigma of ectopic expression of FGFR3 in multiple myeloma: a critical initiating event or just a target for mutational activation during tumor progression. Curr. Opin. Hematol. 9:288-293. (Pubitemid 34596872)
32. Li, J., et al. 2007. Foxn1 promotes keratinocyte differentiation by regulating the activity of protein kinase C. Differentiation. 75:694-701. (Pubitemid 47537528)
33. Lee, D., Prowse, D.M., and Brissette, J.L. 1999. Association between mouse nude gene expression and the initiation of epithelial terminal differentiation. Dev. Biol. 208:362-374. (Pubitemid 29183996)
34. Janes, S.M., Ofstad, T.A., Campbell, D.H., Watt, F.M., and Prowse, D.M. 2004. Transient activation of FOXN1 in keratinocytes induces a transcriptional programme that promotes terminal differentiation: contrasting roles of FOXN1 and Akt. J. Cell Sci. 117:4157-4168.
35. Brissette, J., Li, J., Kamimura, J., Lee, D., and Dotto, G.P. 1996. The product of the mouse nude locus, Whn, regulates the balance between epithelial cell growth and differentiation. Genes Dev. 10:2212-2221. (Pubitemid 26303876)
36. Su, D.M., Navarre, S., Oh, W.J., Condie, B.G., and Manley, N.R. 2003. A domain of Foxn1 required for crosstalk-dependent thymic epithelial cell differentiation. Nat. Immunol. 4:1128-1135. (Pubitemid 37428041)
37. Segre, J.A., Nemhauser, J.L., Taylor, B.A., Nadeau, J.H., and Lander, E.S. 1995. Positional cloning of the nude locus: genetic, physical, and transcription maps of the region and mutations in the mouse and rat. Genomics. 28:549-559.
38. Nehls, M., Pfeifer, D., Schorpp, M., Hedrich, H., and Boehm, T. 1994. New member of the winged-helix protein family disrupted in mouse and rat nude mutations. Nature. 372:103-107. (Pubitemid 24339492)
39. Frank, J., et al. 1999. Exposing the human nude phenotype. Nature. 398:473-474.
40. Schlake, T., Schorpp, M., Nehls, M., and Boehm, T. 1997. The nude gene encodes a sequence-specific DNA binding protein with homologs in organisms that lack an anticipatory immune system. Proc. Natl. Acad. Sci. U. S. A. 94:3842-3847. (Pubitemid 27180460)
41. Weiner, L., et al. 2007. Dedicated epithelial recipient cells determine pigmentation patterns. Cell. 130:932-942. (Pubitemid 47332571)
42. Yugawa, T., et al. 2007. Regulation of Notch1 gene expression by p53 in epithelial cells. Mol. Cell. Biol. 27:3732-3742. (Pubitemid 46726180)
43. Scholl, F.A., Dumesic, P.A., and Khavari, P.A. 2004. Mek1 alters epidermal growth and differentiation. Cancer Res. 64:6035-6040.
44. Ornitz, D.M., et al. 1996. Receptor specificity of the fibroblast growth factor family. J. Biol. Chem. 271:15292-15297. (Pubitemid 26195013)
45. Jin, C., et al. 2004. Directionally specific paracrine communication mediated by epithelial FGF9 to stromal FGFR3 in two-compartment premalignant prostate tumors. Cancer Res. 64:4555-4562. (Pubitemid 38856928)
46. Schreiber, M., et al. 1999. Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev. 13:607-619. (Pubitemid 29131884)
47. van Dam, H., and Castellazzi, M. 2001. Distinct roles of Jun: Fos and Jun: ATF dimers in oncogenesis. Oncogene. 20:2453-2464. (Pubitemid 32531302)
48. Friday, B.B., and Adjei, A.A. 2008. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin. Cancer Res. 14:342-346.
49. Baxter, R.M., and Brissette, J.L. 2002. Role of the nude gene in epithelial terminal differentiation. J. Invest. Dermatol. 118:303-309. (Pubitemid 34158485)
50. Banks-Schlegel, S.P., Gazdar, A.F., and Harris, C.C. 1985. Intermediate filament and cross-linked envelope expression in human lung tumor cell lines. Cancer Res. 45:1187-1197.
51. Rheinwald, J.G., and Beckett, M.A. 1981. Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultures from human squamous cell carcinomas. Cancer Res. 41:1657-1663.
52. Masih-Khan, E., et al. 2006. MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma. Blood. 108:3465-3471. (Pubitemid 44776888)
53. Dunn, C., Wiltshire, C., MacLaren, A., and Gillespie, D.A. 2002. Molecular mechanism and biological functions of c-Jun N-terminal kinase signalling via the c-Jun transcription factor. Cell Signal. 14:585-593. (Pubitemid 34304343)
54. Li, G., et al. 2003. c-Jun is essential for organization of the epidermal leading edge. Dev. Cell. 4:865-877. (Pubitemid 36676038)
55. Schorpp, M., Hofmann, M., Dear, T.N., and Boehm, T. 1997. Characterization of mouse and human nude genes. Immunogenetics. 46:509-515. (Pubitemid 27429855)
56. Lazarov, M., et al. 2002. CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis. Nat. Med. 8:1105-1114. (Pubitemid 35175965)
57. Nguyen, B.C., et al. 2006. Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation. Genes Dev. 20:1028-1042.
58. Mammucari, C., et al. 2005. Integration of Notch 1 and calcineurin/NFAT signaling pathways in keratinocyte growth and differentiation control. Dev. Cell. 8:665-676. (Pubitemid 40585290)
59. Zheng, Y., et al. 2005. Organogenesis from dissociated cells: generation of mature cycling hair follicles from skin-derived cells. J. Invest. Dermatol. 124:867-876. (Pubitemid 40629084)
60. Musti, A.M., Treier, M., and Bohmann, D. 1997. Reduced ubiquitin-dependent degradation of c-Jun after phosphorylation by MAP kinases. Science. 275:400-402. (Pubitemid 27051620)
61. Henderson, J.E., et al. 2000. Expression of FGFR3 with the G380R achondroplasia mutation inhibits proliferation and maturation of CFK2 chondrocytic cells. J. Bone Miner. Res. 15:155-165.